Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Insights - The recent China-SCO (Belarus, Uzbekistan) International Medical and Pharmaceutical Industry Cooperation Conference held in Fangchenggang has led to multiple medical cooperation agreements among China, Belarus, and Uzbekistan [1][3] Group 1: Event Overview - The conference took place on November 26 in Fangchenggang, attended by numerous guests and pharmaceutical representatives from China, Belarus, and Uzbekistan [1] - A signing ceremony resulted in a memorandum of cooperation between the Fangchenggang International Medical Open Experimental Zone and the Belarus "Giant Stone" China-Belarus Industrial Park [3] Group 2: Key Agreements and Achievements - Strategic cooperation framework agreements were signed between the Fangchenggang International Medical Open Experimental Zone and Belarusian companies, focusing on traditional medicine development and personnel training [3] - The "Pearl Eye Drops," produced by Lezhu Pharmaceutical and registered in Belarus, marks a significant breakthrough for Chinese traditional medicine entering the SCO market [3] Group 3: Future Development and Collaboration - Fangchenggang aims to enhance its international medical cooperation with countries in the SCO, ASEAN, and Belt and Road Initiative, having established partnerships with various foreign industrial parks [5] - The Fangchenggang International Medical Open Experimental Zone is developing into a more open and inclusive platform, seeking to build international medical institutions and regional medical centers to provide healthcare services to SCO member states [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-050 西安国际医学投资股份有限公司 关于控股股东解除质押 及一致行动人进行股份质押的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 二、股东股份质押的基本情况 ■ 三、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： ■■ 四、其他说明 1.申华控股本次股份质押融资不涉及用于满足上市公司生产经营相关需求。 2.申华控股未来半年内到期的质押股份累计数量0股，占其持有本公司股份总数的0%，占公司总股本的 0%，对应融资金额为0亿元；未来一年内到期的质押股份累计数量45,310,000股，占其持有本公司股份 总数的74.91%，占公司总股本的2.02%，对应融资金额为0.78亿元。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控股股东陕西世纪新元商业管理有限公司 （以下简称"世纪新元"）及其一致行动人申华控股集团有限公司（以下简称"申华控股"）的通知，2025 年11月26日 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

国际医学公告称，2025年11月26日，控股股东世纪新元解除1912万股质押，占其所持股份比例3.10%， 占公司总股本0.85%；一致行动人申华控股质押2000万股，占其所持股份比例33.07%，占公司总股本 0.89%，质押用途为项目建设。截至公告披露日，世纪新元及其一致行动人累计质押股份47514万股， 占持股总数66.12%，占公司总股本21.22%。申华控股未来一年内到期质押股份对应融资金额0.78亿元， 本次质押风险可控，不会导致公司实控权变更。 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-050 西安国际医学投资股份有限公司 关于控股股东解除质押 及一致行动人进行股份质押的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）及其 一致行动人申华控股集团有限公司（以下简称"申华控股"）的通知， 2025年11月26日世纪新元使用其持有的本公司部分股份与开源证券股 份有限公司进行的股票质押式回购交易已办理了解除质押。同日，申华 控股使用其持有的本公司部分股份与开源证券股份有限公司进行了股 票质押式回购交易，具体事项如下： 二、股东股份质押的基本情况 | | 是否为控股股 | 本次质押 | 本次质押 | 本次质押 | 是否为 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 东或第一大股 | | | | | 为补 | 质押起 | 质押到 ...

Core Viewpoint - The company emphasizes its focus on health care services and modern medical technology application, highlighting its commitment to investor returns and ongoing development despite current operating losses [1] Group 1: Company Overview - The company operates two major comprehensive medical campuses: Xi'an High-tech Hospital and Xi'an International Medical Center Hospital, with a service capacity of ten thousand beds [1] - The company is equipped with internationally advanced hardware, including the upcoming proton therapy center, the first of its kind in Northwest China [1] - The medical team consists of highly qualified professionals, including "National Famous Doctors," professors from top-tier institutions, and experts receiving government special allowances [1] Group 2: Financial Performance and Investor Returns - Since its transformation in 2019 to focus on medical services, the company is in a growth phase, with new medical projects gradually coming online [1] - Although the company has been narrowing its net profit losses, it has not yet achieved profitability, and its revenue scale has not yet covered operational costs and expenses [1] - The company has consistently aimed to provide stable and sustainable dividends to shareholders when conditions allow [1]

Core Viewpoint - The company is actively engaged in research and application of brain-machine interface systems, integrating them with rehabilitation technologies to enhance patient care [2]. Group 1 - The company has introduced rehabilitation training systems that combine brain-machine interfaces with exoskeleton robots and functional electrical stimulation devices [2]. - The company is conducting surgeries related to deep brain stimulation, spinal cord nerve stimulation, and vagus nerve stimulation as part of its rehabilitation efforts [2].

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-21 | 4.61 | -3.76% | -1389.58万 | -9.12% | 687.76万 | 4.52% | 701.82万 | - 4.61% | | 2025-11-20 | | 4.79 -1.24% | -982.70万 | -16.01% | 504.71万 | 8.22% | 477.99万 | 7.79% | | 2025-11-19 | | 4.85 -1.22% | -345.72万 | -5.09% | -79.97万 | -1.18% | 425.69万 | 6.26% | | 2025-11-18 | 4.91 | -1.01% | -1296.48万 | -16.49% | 131.77万 | 1.68% | 1164.72万 | 14.82% | | 2025-11-17 | 4.96 0.00% | | -257.27万 ...

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 5.5 yuan, compared to the current price of 4.79 yuan [3][7]. Core Insights - The company reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%. The net profit attributable to the parent company was a loss of 294 million yuan, with a year-on-year increase in losses of 38.45% [2][7]. - The decline in revenue is attributed to two main factors: adjustments in medical insurance payment policies leading to a decrease in inpatient service volume and the ongoing reform of the DRG payment method, which has reduced the average cost per inpatient [7]. - Despite the short-term pressure on revenue, the company has seen a steady increase in outpatient and emergency services, with a total of 1.9751 million visits, a year-on-year increase of 4.03% [7]. - The company is focusing on strategic growth areas, including high-barrier projects like the proton therapy center, consumer healthcare, and data assetization, which are expected to enhance long-term competitiveness [7]. Financial Summary - For 2025, the company is projected to have total revenue of 4.055 billion yuan, a decrease of 15.8% year-on-year, with a net profit attributable to the parent company expected to be a loss of 343 million yuan [2][8]. - The company’s financial metrics indicate a projected net profit growth rate of 74.5% in 2026 and 214.8% in 2027, suggesting a potential recovery in profitability [8]. - The company’s total assets are estimated to be 10.422 billion yuan in 2025, with a debt-to-equity ratio of 164.2% [8].